Univest Securities, LLC Announces Closing of $3.0 Million Registered Direct Offering for its Client AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC)
07 April 2023 - 10:10AM
Univest Securities, LLC (“Univest”), a member of FINRA and SIPC,
and a full-service investment bank and securities broker-dealer
firm based in New York, today announced the closing of registered
direct offering (the “Offering”) of 625,000 American Depositary
Shares (“ADSs”) priced at $4.00 per ADS, with pre-funded warrants
exercisable for 125,000 ADSs and warrants exercisable for 750,000
ADSs for its client AnPac Bio-Medical Science Co., Ltd. (Nasdaq:
ANPC) (the “Company” or “AnPac”), a company with operations in the
United States and China focused on early cancer screening and
detection and plans to enter into the operation of a
business-to-business e-commerce food platform focused on the sale
of Asian sourced food products.
In connection with such offering, the Company
sold to the institutional investors a total of 625,000 ADSs priced
at $4.00 per ADS, pre-funded warrants exercisable for 125,000 ADSs
and warrants exercisable for 750,000 ADSs. The purchase price of
each pre-funded warrant is equal to the offering price per ADS,
minus $0.0001, and the exercise price of each pre-funded warrant is
equal $0.0001 per share. The pre-funded warrants are immediately
exercisable and may be exercised at any time until exercised in
full. The warrants are immediately exercisable, expire five (5)
years from the original issuance date and have an exercise price of
$4.00 per ADS. The Company also issued to Univest Securities, LLC,
which acted as the sole placement agent for the offering, warrants
exercisable for 37,500 ADSs, with an exercise price of $4.80.
The gross proceeds to the Company from the
registered direct offering were approximately $3.0 million before
deducting the placement agent’s fees and other offering
expenses.
The ADSs, the pre-funded warrants, the warrants
and the ADSs underlying the pre-funded warrants, the warrants and
the placement agent’s warrants were offered pursuant to a
prospectus supplement to a shelf registration statement on Form F-3
(File No. 333-256630) previously filed and declared effective by
the U.S. Securities and Exchange Commission (“SEC”) on June 7, 2021
(the “Shelf Registration Statement”). Such offering was made only
by means of such prospectus supplement, which was filed by the
Company with the SEC on April 4, 2023. Copies of the prospectus
relating to the Offering may be obtained from Univest by email at
info@univest.us, or by calling +1 (212) 343-8888. In addition,
copies of the prospectus relating to the Offering may be obtained
via the SEC's website at www.sec.gov.
This press release does not constitute an offer
to sell, or the solicitation of an offer to buy, any of the
Company’s securities, nor shall there be any offer, solicitation or
sale of any of the Company’s securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction.
About Univest Securities,
LLC
Registered with FINRA since 1994, Univest
Securities, LLC provides a wide variety of financial services to
its institutional and retail clients globally including brokerage
and execution services, sales and trading, market making,
investment banking and advisory, wealth management. It strives to
provide clients with value-add service and focuses on building
long-term relationship with its clients. For more information,
please visit: www.univest.us.
About AnPac
Bio-Medical Science Co., Ltd.
AnPac Bio-Medical Science Co., Ltd. is a
biotechnology company focused on early cancer screening and
detection, with 155 issued patents as of March 31, 2023. With two
certified clinical laboratories in China and one CLIA and CAP
accredited clinical laboratory in the United States, AnPac Bio
performs a suite of cancer screening and detection tests, including
CDA (Cancer Differentiation Analysis), bio-chemical, immunological,
and genomics tests. The Company intends to enter the
business-to-business e-commerce food business with the formation of
its wholly-owned subsidiary Fresh2 Technology Inc and the
acquisition of Fresh2 Ecommerce Inc.
Forward-Looking Statements
This press release contains forward-looking
statements as defined by the Private Securities Litigation Reform
Act of 1995. Forward-looking statements include statements
concerning plans, objectives, goals, strategies, future events or
performance, and underlying assumptions and other statements that
are other than statements of historical facts. When the Company
uses words such as “may, “will, “intend,” “should,” “believe,”
“expect,” “anticipate,” “project,” “estimate” or similar
expressions that do not relate solely to historical matters, it is
making forward-looking statements. Forward-looking statements are
not guarantees of future performance and involve risks and
uncertainties that may cause the actual results to differ
materially from the Company’s expectations discussed in the
forward-looking statements. These statements are subject to
uncertainties and risks including, but not limited to, the
uncertainties related to market conditions and the completion of
the initial public offering on the anticipated terms or at all, and
other factors discussed in the “Risk Factors” section of the
registration statement filed with the SEC. For these reasons, among
others, investors are cautioned not to place undue reliance upon
any forward-looking statements in this press release. Additional
factors are discussed in the Company’s filings with the SEC, which
are available for review at www.sec.gov. Univest Securities
LLC and the Company undertakes no obligation to publicly revise
these forward-looking statements to reflect events or circumstances
that arise after the date hereof.
For more information, please contact:
Univest Securities, LLC
Edric Guo
Chief Executive Officer
75 Rockefeller Plaza, Suite 18C
New York, NY 10019
Phone: (212) 343-8888
Email: info@univest.us
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Apr 2023 to Apr 2024